increased risk of metastasis in colorectal cancer. PrPc defines a subpopulation of and aldehyde dehydrogenase 1 (ALDH1) (11) (12) (13) . Previous studies by ourselves and 13 other authors have shown that as few as 100 CD44 + cancer cells isolated from patients 14 were able to develop into a heterogeneous tumor, and that spheroids derived from a 15 single CD44 + cancer cell could recapitulate the heterogeneous hierarchy of tumor cells 16 (8,14) . These studies indicate that CCSCs may trigger the formation of colorectal cancer 17 (CRC), and that CD44 is a functionally important surface biomarker of CCSCs. 18 Importantly, an antibody specific to CD44 selectively eradicated leukemic stem cells in 19 vivo by altering the fate of leukemic stem cells (15). Monoclonal antibodies targeting 20 surface antigens specifically expressed in CSCs offer a potentially powerful strategy to 21 eliminate CSCs with minimal toxicity. Besides CD44, monoclonal antibodies targeting 22 CD123 and CD47 have been reported to eradicate leukemia stem cells (16) . 23 24 Recent evidence suggests that CSCs may be endowed with enhanced disseminating (17) (18) (19) . Although CD44 and some other adhesion molecules, such as E-cadherin, could 2 act as migration suppressors by restricting cancer cells to their primary sites (20) , these 3 same molecules with certain modifications (e.g., splice variants of CD44) or in 4 combination with other adhesion molecules, such as CD26, may result in metastatic 5 phenotypes (21-24). 6 7 Cellular prion protein (PrPc) is a highly-conserved glycoprotein present in all vertebrates 8 and has the same protein sequence as the scrapie prion protein (PrPsc), a pathogenic factor 9 in scrapie in sheep， bovine spongiform encephalopathy in cattle, and kuru in human beings 10 (25, 26 
Results

1
The PrPc expression level is correlated with clinical and pathological features and 2 outcomes in CRC patients.
3
On the basis of our previous observations that CD44 is a robust marker for CCSCs (14) , 4 we hypothesized that additional factors may exist that are co-expressed with CD44 in the 5 promotion of migration and metastasis of CSCs. We therefore compared gene expression 6 in colorectal cancer, liver metastases and normal tissues by cDNA array performed in our 7 lab. In addition, we conducted a CD44 co-expression analysis from Oncomine datasets 8 (Ki_Colon, Koinuma_Colon, and Smith_ Colorectal_2 datasets; 33-35). Interestingly, we 9 found that several genes were in fact co-expressed with CD44 and up-regulated in 10 metastases; one of these genes was PRNP (data not shown), which encodes PrPc. (Fig. 1A) . The PrPc expression level was significantly higher in 17 poorly-differentiated than in moderately-and well-differentiated samples (P < 0.001; Fig.   18 1A and Supplementary Fig. S1A ), whereas the level of CD44 was not associated with 19 clinical stage (P = 0.143) (Fig. 1A) . This observation was supported by examining 20 multiple Oncomine cDNA microarray datasets, which revealed that the PRNP mRNA 21 expression levels were significantly elevated in high-grade and advanced-stage CRCs 22 ( Supplementary Fig. S1B ). Importantly, the CRC patients with the highest PrPc 23 expression were also found to have the poorest prognosis, with a median survival of only 24 12 months (Fig. 1B) , which was significantly (P < 0.0001) shorter than that of patients primary tumors of the patients with liver or lung metastasis (P = 0.0007) (Fig. 1C) . 6 Oncomine cDNA microarray data analysis also showed a close correlation of the PrPc 7 level with disease recurrence and early patient death ( Supplementary Fig. S1C ). We also 8 observed that PrPc expression was most prominent at the interface and invasion fronts of 9 tumor nodules (identified by cytokeratin 20 staining; Fig. 1D ), which may constitute a 10 reservoir of mobile CSCs (36). In the lymph nodes that had been invaded by CRC cells, 11 
PrPc
+ cells were also observed in vascular invasions ( Fig. 1E and Supplementary Fig.   12 S1D). In addition, high levels of PrPc were present in CRC cells and could be seen 13 invading the tumor stroma (Fig. 1F) were detected in the third transplantation ( Supplementary Fig. S2D and data not shown). Table 2 ). As shown in 14 Supplementary Figure S2E , the reconstituted tumors were histologically heterogeneous. Since CSC is generally rare and it is difficult to label and trace its growth in animals, we 10 generated a cell line of CD44 + CCSCs isolated from a CRC patient. These cells have all 11 the characteristics of CSCs including constitutive expression of CD44, and the capacity 12 to form spheres and generate xenograft tumors (14) . The CCSCs were grown in ultra-low 13 attachment dishes without serum, and were subcultured once a week for fewer than 20 14 passages. To investigate the unique role of PrPc in metastasis, we used this cell line 15 pre-labeled with DsRed and in which PrPc had either been knocked down by shRNAs or 16 was over-expressed via the pBABE-PURO retrovirus system. As shown in Figure 4A -C, 17 PrPc knockdown strongly inhibited tumor growth and liver metastasis as assessed by 18 whole-body fluorescence imaging and H&E staining, suggesting that PrPc play a central 19 role in CSC metastasis. In contrast both tumor growth and liver metastasis were 20 promoted by PrPc over-expression. Moreover, the level of PrPc expression was 21 correlated with the metastatic index (Fig. 4D) . Similar results were observed using the Supplementary Fig. S4D ). Using CRC cells with CSC properties, we were able to 1 demonstrate that PrPc is functionally required for the migration of CCSCs and 2 contributes to CRC metastasis. Surface markers unique to CSCs would provide ideal therapeutic targets on these cells, 6 and indeed monoclonal antibodies have demonstrated therapeutic efficacy in both 7 preclinical tumor models and cancer patients (41) . We were therefore interested in 8 addressing the question of whether PrPc could be used as a therapeutic target, in a 9 manner similar to CD44 (15). We generated several monoclonal antibodies against PrPc, 10 out of which we selected the IgG1 antibody. The specificity of the antibodies was 11 verified by ELISA, Western blotting (WB), and IHC staining ( Supplementary Fig.   12 S4E-G). The migration of CD44 + CCSCs in vitro was strongly inhibited after they had Fig. S4H ). Fig. S4I ).
14
PrPc promotes EMT in CCSCs
15
We consistently observed that the PrPc-overexpressing CCSCs exhibited an elongated 16 mesenchymal-like morphology, whereas the PrPc knockdown cells were flatter ( Fig. 5A ; 17 Supplementary Fig. S4G ). Also, PrPc + CRC cells generated branching colonies with 18 loose cell-cell interaction (see Fig. 2D whereas E-cadherin, an epithelial marker, was down-regulated ( Supplementary Fig. S5A ). 1 In addition, there were increased levels of matrix metalloproteinase 2 (MMP2) and 2 MMP11 ( Supplementary Fig. S5A ), which might have contributed to the metastasis 3 observed in PrPc over-expressing cells. In contrast, knock-down of PrPc resulted in a 4 reversed-expression pattern (Supplementary Fig. S5A ). Western blot analysis and double 5 IF staining further confirmed the correlation of PrPc with the expression of EMT-related 6 molecules ( Fig. 5B-C; Supplementary Fig. S5B ). Supplementary Fig. S5A ), we reasoned that PrPc might regulate EMT via Twist. 11 To test this, Twist was ectopically expressed in CCSCs in which PrPc was stably knocked 12 down by shRNA. We observed that constitutively overexpressed Twist was indeed able 13 to induce EMT in PrPc-knocked down CCSCs, leading to increased levels of Snail and 14 N-cadherin (Fig. 5D) . However, overexpression of PrPc in the Twist RNAi cells was 15 unable to restore EMT, probably because Snail and N-cadherin expression was lower 16 than in the parental cells (Fig. 5D) dose-dependent manner, (Fig. 6C-D) , probably via interference with the interaction 19 between laminin and its receptor PrPc. IF staining confirmed that the anti-PrPc antibody 20 attenuated the laminin-induced N-cadherin expression (Fig. 6E ). In addition, transwell 21 migration assays revealed that U0126 blocked the PrPc overexpression-induced 22 migration, and that the anti-PrPc antibody also attenuated laminin-enhanced migration 23 ( Fig. 6F) . Our findings thus suggest that ERK2 signaling pathway is involved in 24 PrPc-induced EMT. 
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